Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P54289

UPID:
CA2D1_HUMAN

ALTERNATIVE NAMES:
Voltage-gated calcium channel subunit alpha-2/delta-1

ALTERNATIVE UPACC:
P54289; Q17R45; Q9UD80; Q9UD81; Q9UD82

BACKGROUND:
The alpha-2/delta subunit of voltage-dependent calcium channels, identified as P54289, is crucial for modulating calcium channel function. This includes influencing the density of calcium currents and the kinetics of channel activation and inactivation, essential for proper cellular function and signaling.

THERAPEUTIC SIGNIFICANCE:
Given its association with Developmental and epileptic encephalopathy 110, a disease marked by profound developmental delays and seizures, the alpha-2/delta subunit represents a significant target for drug discovery. Exploring its function could unveil new therapeutic avenues for managing this and potentially other related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.